YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

140 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 141 In stock
USD 88 In stock
USD 151 In stock
USD 340 In stock
USD 563 In stock
USD 970 In stock
USD 1600 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 140 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NGnIfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG3NkBp MXLEUXNQ NHXlOHRKSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2= MoT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
M-07e MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LtdVczKGh? NUnBNWxDTE2VTx?= MWLJR|UxRTBwMESwJOKyKDBwMEGzJO69VQ>? NVjy[mJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
THP-1 NH2yUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;EO|IhcA>? NX7WdHJQTE2VTx?= Mke1TWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? NX3xO3p5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
CMK MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu3NkBp NGXtT2tFVVOR NWrpSY5mUUN3ME2wMlA2OyEEsTCwMlAxQSEQvF2= MonKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
MV4-11 MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfVO|IhcA>? NH75SnpFVVOR MYDJR|UxRTBwMEW1JOKyKDBwMEK4JO69VQ>? MkTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
AML-193 M3rOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nRXVczKGh? MWPEUXNQ Ml;3TWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? NWnqeWNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
HL-60 NHLYRnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LtZlczKGh? M1exXWROW09? NH3P[5FKSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
ML-2 NHvlbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqzO|IhcA>? M4fieWROW09? MX;JR|UxRTBwMEC5JOKyKDBwMECyJO69VQ>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
OCI/AML3 NVTl[oE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX63NkBp NVXz[WFlTE2VTx?= MY\JR|UxRTBwMEGxJOKyKDBwMECyJO69VQ>? NHi1UXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
HEL M1vnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z6PFczKGh? M{HuUWROW09? NHe3eXNKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
ME-1 NXO2cWI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vMSVczKGh? MYPEUXNQ MYDJR|UxRTBwNki0JOKyKDBwMUe5JO69VQ>? M4jG[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
THP-1 MlfhRZBweHSxc3nzJGF{e2G7 NFm3NZkyyqEQvF2= NGDDdZk4OiCq NGHWSYtFVVOR MnXjbY5lfWOnczDhdI9xfG:|aYO= NF:5SVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
M-07e NFracIFHfW6ldHnvckBCe3OjeR?= NYHpWXZOOOLCk{JCpO69VQ>? NWjtZnQ{PzJiaB?= NGfxN5VFVVOR MX3pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NEjFVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
THP-1 NIHHT4xHfW6ldHnvckBCe3OjeR?= MWiw5qCUOcLizszN NXT5WWJmPzJiaB?= MV;EUXNQ Mk\QbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NHW5T5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
CMK Mnr2SpVv[3Srb36gRZN{[Xl? M3nXOFDjiJNzwrFOwG0> MVq3NkBp MX;EUXNQ NF;4PJVqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu M1nQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
AML-193 NFrIcG5HfW6ldHnvckBCe3OjeR?= NYTuW|l5OOLCk{JCpO69VQ>? M2nCc|czKGh? NHKxZZhFVVOR MXnpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NHXaeGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
Kasumi-1 NEjPb2FHfW6ldHnvckBCe3OjeR?= M1S4cFDjiJNzwrFOwG0> M4ru[|czKGh? M{jGSmROW09? NUHtWJlrcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NFq4T3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
MV4-11 NUPWRZZ4TnWwY4Tpc44hSXO|YYm= NIX3PG0x6oDVMdMg{txO NHzaRok4OiCq NVe5bGRZTE2VTx?= MoC1bY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= Ml7JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
MUG-Chor  M2XNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XHblAuPSEQvF2= MlHVNlQwPDhiaB?= NGXEcGlKSzVyPUeuNFXjiImwTTDmc5IhPDiq MmOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NECxPFUoRjJ3NkSwNVg2RC:jPh?=
U-CH1  MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMVUh|ryP NX:4fVJlOjRxNEigbC=> M3XVfWlEPTB;OT6wN-KBkW6PIH\vdkA1QGh? M{iyPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkSwNVg2Lz5{NU[0NFE5PTxxYU6=
KATOIII NYTkOlhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxNE8zOCCwTR?= NYX4[JFIPDhiaB?= Ml3lbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1rkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO1NFU2Lz5{NU[zOVA2PTxxYU6=
AGS  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNE8zOCCwTR?= NV30bYhGPDhiaB?= M2LJRYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHjScow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zOVA2PSd-MkW2N|UxPTV:L3G+
SACC-83 NGTjb2NHfW6ldHnvckBCe3OjeR?= MVi1JI5O NITRdXA1QCCq Mnv3[IVkemWjc3XzJI52[2ynYYKg[ZhxemW|c3nvckBw\iCKSV[tNe6y M2DseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEi1OlM2Lz5{NUS4OVY{PTxxYU6=
INA-6 NWmyfm81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXxWotoOC13MECgcm0> MXW0PEBp M1i1OolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHToT2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
U-266 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vPYI5OC13MECgcm0> M37NNlQ5KGh? M{jYbYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1rqb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
MOLP-8 NF\hd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTmNE02ODBibl2= MUG0PEBp NYOwWIIzcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFLYOWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
HG-1 M4TJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33WZlAuPTByIH7N NYftVHFrPDhiaB?= M3zGNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEPxUYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
NCI-H929 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnHc5VZOC13MECgcm0> MUm0PEBp M4[4cYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEj6fHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
OPM-2 NHnlNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHqfZQ6OC13MECgcm0> MkTlOFghcA>? MonIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
L-363 NGKx[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLrb3IxNTVyMDDuUS=> M1:wR|Q5KGh? NInxb2FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MOLP-2 NEPRd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXUNE02ODBibl2= MkS3OFghcA>? M1rScYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3LyRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
KMS-12-BM NUfJbIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BVYsxNTVyMDDuUS=> M3T3ZlQ5KGh? NGnJVXRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M37hdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
SK-MM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXNRYtvOC13MECgcm0> NVzlR2NoPDhiaB?= M13NPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
U-266 M334c2Fxd3C2b4Ppd{BCe3OjeR?= MU[wMVUxKG6P M3HreFI1KGh? M1zISolv\HWlZYOgZZBweHSxc3nz NYHQd5pTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
INA-6  MmXSRZBweHSxc3nzJGF{e2G7 NVnaeY92OC13MDDuUS=> MYmyOEBp M13PV4lv\HWlZYOgZZBweHSxc3nz MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MCF7 NGDxUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFXVczKGh? NH31SZVKSzVyPUGzJOKyKDZibl2= NUfLNWp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamR6 NH\yOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXIWIc4OiCq MnXzTWM2OD16INMxJFYhdk1? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
MCF7-TamR7 NEP5fnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\vWFU4OiCq Mo\FTWM2OD16INMxJFMhdk1? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{MEKyOUc,OjV{MkCyNlU9N2F-
MCF7-TamR8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOxO|IhcA>? MojqTWM2OD1zNTFCtUA3KG6P MknaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
MCF7-TamC3 NXTub2dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne5O|IhcA>? MnK4TWM2OD14INMxJFMhdk1? M4LjeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamC6 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrGOZB1PzJiaB?= NV7WeIVKUUN3ME22JOKyKDBwMTDuUS=> NEjBSYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MDA-MB-231 M2fkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TOcVczKGh? MlPrTWM2OD13INMxJFEhdk1? MlvXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
SK-BR-3 M1mw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITK[Gw4OiCq Mn:zTWM2OD15INMxJFAvOyCwTR?= NUTlTZR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
Eca109 NF[wNJhHfW6ldHnvckBCe3OjeR?= Mm\PNU02OCCwTR?= NYW2SWRQPDhiaB?= NFWwflJFVVOR M16zeZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 Mme2SpVv[3Srb36gRZN{[Xl? M3\uOVEuPTBibl2= NVPUWIFYPDhiaB?= NYTIUlJjTE2VTx?= MkfPd5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
Eca109 NGmyVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HL[|AuOTByIH7N MnLWNlQwPDhiaB?= M1;yVWROW09? NIfUSW5l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 M2TneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi5eXBoOC1zMECgcm0> NFruUYwzPC92ODDo MWLEUXNQ M3v0WoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXvyRmk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN|k{QTVpPkK1NVM6Ozl3PD;hQi=>
MT-3 MWnLbY5ie2ViQYPzZZk> MVu3NkBp NGSyZnFFVVOR NYD0bWRYUUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NIe3bZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MDA-MB-468 NUPJWmpWU2mwYYPlJGF{e2G7 NFnVcWI4OiCq MoT1SG1UVw>? NIK4b5NKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? Mmm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
SUM-159 Mm\MT4lv[XOnIFHzd4F6 MoqyO|IhcA>? MYfEUXNQ NGLzfJdKSzVyPUGuO|IhyrFiMD6zN{BvVSCob4KgSHI1KGW6cILld5Nqd25? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MT-3 M4T6WWtqdmG|ZTDBd5NigQ>? NFzGN4c4OiCq NYfhSld{TE2VTx?= MWjJR|UxRTV2LkGxJOKyKDRwM{Kgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NV\oTZJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MDA-MB-468 MWDLbY5ie2ViQYPzZZk> NHj1VWo4OiCq NG\yOVZFVVOR Ml72TWM2OD1yLkC3JOKyKDBwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NH7i[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
SUM-159 NFPXPZpMcW6jc3WgRZN{[Xl? NEf1XIk4OiCq MX;EUXNQ NGDPfYNKSzVyPU[5MlQhyrFiND6yN{BvVSCob4KgSHI2KGW6cILld5Nqd25? NH\sW|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + NAC MmH4T4lv[XOnIFHzd4F6 MV[3NkBp NXj5XFFnTE2VTx?= MYjJR|UxRTV4LkKgxtEhOi5yNzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NFH3W|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + SB203580 NUf4TpQyU2mwYYPlJGF{e2G7 NF3lbZE4OiCq NIfI[ZVFVVOR NHTiR5dKSzVyPUO4MlQyKMLzIEWuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
DB MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fWTFExKG6P M4roRlI1KGh? NV25SHh3TE2VTx?= NFHHSoNqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
SU-DHL-8 M2PKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH36b5UyOCCwTR?= MYiyOEBp MmDUSG1UVw>? NELh[ZlqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NFPjSFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4OlU6PSd-MkS0PFY2QTV:L3G+
WSU-DLCL2 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjSc21ROTBibl2= Mo\BNlQhcA>? MmX4SG1UVw>? Mk\lbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M2fh[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
ACC-2 NELUPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HTO|AuOTByIH7N M4DIflI1KGh? NF\kSJdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX;oUoxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
ACC-2 MWTBdI9xfG:|aYOgRZN{[Xl? Mny1NE0zOCCwTR?= MVyyOEBp NIPD[nVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHrCVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3NFk6PSd-MkSzO|A6QTV:L3G+
ACC-2 NFLQOmNHfW6ldHnvckBCe3OjeR?= MnfGNE0zOCCwTR?= M{O1WVI1KGh? M4XuRolv[3KnYYPld{B1cGViY3;ueoVze2mxbjDv[kBNSzOLIITvJGxEO0mL NX;nSJVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzO|A6QTVpPkK0N|cxQTl3PD;hQi=>
BFTC905 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjweVVCOC1zMECwJI5O M3\GUFQ5KGkEoB?= NHzkOGxFVVOR MWDJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3z2RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
T24 NX7FTlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf1NE0yODByIH7N MlLMOFghcMLi NVjpVVJuTE2VTx?= MnmyTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{[0OEc,OjR{OUe2OFQ9N2F-
TSGH8301  M1jMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRdm1ZOC1zMECwJI5O NFzEdFY1QCCqwrC= NFixcnNFVVOR MWfJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4njR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm3OlQ1Lz5{NEK5O|Y1PDxxYU6=
BFTC909 M{XBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDBd5V6OC1zMECwJI5O NU\ud|lnPDhiaNMg NXjwWXBvTE2VTx?= MX3JR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
BFTC905 NGKyS|VCeG:ydH;zbZMhSXO|YYm= MoXYNlAhdk1? M3W4e|Q5KGh? M2jRfGROW09? NH6wbmdqdmS3Y3XzJIFxd3C2b4Ppdy=> NFq5NWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905 NULXd5NVTnWwY4Tpc44hSXO|YYm= MYCyNEBvVQ>? MWO0PEBp NHXjbndFVVOR M2\YXoRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ NXmzeoNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVc3PDRpPkK0Nlk4PjR2PD;hQi=>
A2780p M3n5S2Z2dmO2aX;uJGF{e2G7 MXmwMVExOCCwTR?= M165e|I1KGh? NEPSXFJFVVOR NGfBOnJqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC= M3fZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[yPFc2Lz5{NEK2Nlg4PTxxYU6=
A2780cis M3PPe2Z2dmO2aX;uJGF{e2G7 M2\YU|AuOTByIH7N NIjGd|gzPCCq MkHtSG1UVw>? MnnjbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi NFTvXIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK2Nlg4PSd-MkSyOlI5PzV:L3G+
A2780p MnzIRZBweHSxc3nzJGF{e2G7 M13ZWVUuOTByIH7N M162O|I1NzR6IHi= NIjxOHlFVVOR Mnj0bY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M2HKOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mk[yPFc2Lz5{NEK2Nlg4PTxxYU6=
A2780cis NIrzOlZCeG:ydH;zbZMhSXO|YYm= M3e3cVUuOTByIH7N MYeyOE81QCCq M3LqSGROW09? MmXpbY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NWP5TZU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlI5PzVpPkK0NlYzQDd3PD;hQi=>
SH-SY5Y MWrBdI9xfG:|aYOgRZN{[Xl? MUSxM|ExNzFyMDFCuW0> NXi3S2Q6PzJiaB?= M4HsTGROW09? NXv1S|VKcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mmm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{NUS1OlAoRjJ2MkW0OVYxRC:jPh?=
HL-60 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi3NuKhcA>? M{jFU2ROW09? MoTQTWM2OD1yLkOgcm0> NHuzVW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPFg3Oid-MkO2NVg5PjJ:L3G+
U937  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXPXIl2PzMEoHi= NI\xfWFFVVOR MkO2TWM2OD1yLkigcm0> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
HL-60  MlTISpVv[3Srb36gRZN{[Xl? MW[xxsDPxE1? M1XMTlYwOTJxMkSgbC=> MYnEUXNQ NVfOd3dqcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
U937  MkjmSpVv[3Srb36gRZN{[Xl? MlftNeKh|ryP NFflWoY3NzF{L{K0JIg> NGLFWXJFVVOR MVPpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= M13nUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG4PFYzLz5{M{[xPFg3OjxxYU6=
HL-60 MYTBdI9xfG:|aYOgRZN{[Xl? NYqxbox1OC5zL{Gg{txO NGf4bnU5KGh? M3nMWWROW09? M3PuW4lv\HWlZYOgZZBweHSxc3nz MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
Sk-NEP-1  Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrGZppzOS1zMECwNEBvVQ>? M{fublI1KGh? M4G5cGROW09? MV7JR|UxRTFyMDDuUS=> NGn3XoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K2O|Y6QSd-MkOyOlc3QTl:L3G+
SK-NEP-1  NULse5k2SXCxcITvd4l{KEG|c3H5 NUTCRph[PTBxMUCwJI5O NYLxUm93OTJxMkSgbC=> MmD5SG1UVw>? MVjpcoR2[2W|IHHwc5B1d3Orcx?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ4N{[5PUc,OjN{Nke2PVk9N2F-
TC-32 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;pWlAvOS1zMECwJI5O MkTZSWM2OD1|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVO4XXd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OlE4PjNpPkKyPVYyPzZ|PD;hQi=>
TC-71 NEe2d3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuwMlEuOTByMDDuUS=> M2rhW2VEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
SK-ES-1 NF3tNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmNE4yNTFyMECgcm0> NGqwfnJGSzVyPUKuPEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
RD-ES MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSzNE4yNTFyMECgcm0> M1vr[2VEPTB;Nj6yJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
HEK293 NVrjOpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WxfVAvOS1zMECwJI5O NVW5XHJDTUN3ME2yN{4xKG6PLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
M059J MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELzO2IxNTVyIH7N Mk\MOFghcA>? NEDZVYxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
M059K NEO4UpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3TXYR3OC13MDDuUS=> MX:0PEBp MmLkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH\aWJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059J NUS5XoZqSXCxcITvd4l{KEG|c3H5 NWr0[|FwOzBibl2= M3jDXlI1KGh? NUnwW4VCcW6mdXPld{BieG:ydH;zbZM> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
M059K MU\BdI9xfG:|aYOgRZN{[Xl? Mnf3N|Ahdk1? MlLGNlQhcA>? NIDJb|hqdmS3Y3XzJIFxd3C2b4Ppdy=> NYDlNFNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3O|AyOTBpPkKyO|cxOTFyPD;hQi=>
PANC-1 M2fCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\UNE4xOS1zMECwJI5O M37Pc|Q5KGh? MlzLTWM2OD1|Lk[5JI5O NHvXb2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
MIAPaCa-2 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlAyNTFyMECgcm0> NUnnbpdbPDhiaB?= M4PGVmlEPTB;MkmuN|Yhdk1? MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
BxPC-3 M1\0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknCNE4xOS1zMECwJI5O MU[0PEBp MkH0TWM2OD1|MD6yOkBvVQ>? NVX5[IZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
PANC-1 NFzmc25HfW6ldHnvckBCe3OjeR?= MU[wMVExODBibl2= M2\zUFI1KGh? M1vmbIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NYnCTHRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
MIAPaCa-2 NXq0dldWTnWwY4Tpc44hSXO|YYm= Ml3BNE0yODByIH7N M2\OZ|I1KGh? MkDNbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u MonMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MkO4O|EoRjJ{N{KzPFcyRC:jPh?=
BxPC-3 NETjVFNHfW6ldHnvckBCe3OjeR?= NYLZd4ppOC1zMECwJI5O NWG3NXVJOjRiaB?= M{P1[Ilv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> M4jPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN|g4OTxxYU6=
RPMI-7951 M4Ly[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvHTVUxRTNwMjDuUS=> MlTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
SK-MEL-5 M4rlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnzT5BIUTVyPUSuNkBvVQ>? NFHZeIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezO|UxOid-MkG3N|c2ODJ:L3G+
A375 NWrzd4JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuxZ4pTT0l3ME22MlMhdk1? NUj6dlFHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
SK-MEL-28 NGfheXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3BSmVIUTVyPUeuOkBvVQ>? NX\tS5lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N|c2ODJpPkKxO|M4PTB{PD;hQi=>
SK-MEL-2 NEfmeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;qXVdIUTVyPUGxJI5O MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
DB NHTS[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\HUVJ7PDkEoHi= MWDHTVUxRTNwNTDuUS=> NXrvZmlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyN|c2ODhpPkKxNlM4PTB6PD;hQi=>
Pfeiffer Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX5ZlVVPDkEoHi= NVjTVYlMT0l3ME2zMlkhdk1? NXHrelhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyN|c2ODhpPkKxNlM4PTB6PD;hQi=>
SU-DHL-5 NF;rd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe0POKhcA>? M1S0c2dKPTB;MD6yN{BvVQ>? M1rrdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
SU-DHL-8 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\hXHI5PDkEoHi= MUHHTVUxRTFwNDDuUS=> M3nvZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkO3OVA5Lz5{MUKzO|UxQDxxYU6=
WSU-DLCL-2 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW0POKhcA>? MX;HTVUxRTFwNDDuUS=> MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
A549 NEfVNYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1PGUmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMtKEmFNUC9NE4xOTN2zszN M4DhTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N|c1Lz5{OEixOFM4PDxxYU6=
DU145 NX3LUFVnS3m2b4TvfIlkcXS7IHHzd4F6 MmL6R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[nliTWTUJIF{e2G7LDDFR|UxRTBwMEGzPO69VQ>? MnfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5N{S0NlYoRjJ6N{e0OFI3RC:jPh?=
PC3 M17YXmN6fG:2b4jpZ4l1gSCjc4PhfS=> M1fqSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{BjgSCPVGSgZZN{[XluIFXDOVA:OC5yOUNOwG0> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd5NESyOkc,Ojh5N{S0NlY9N2F-
A549 MoXUSpVv[3Srb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKFCDS{GgbY4hcHWvYX6gRVU1QSClZXzsd{whUUN3ME2wMlXPxE1? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO|Q9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01023386 Completed Drug: YM155 Cancer Astellas Pharma Inc November 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID